Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Drug Type
3.3. Snippet by End-user
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Incidence of cancer
4.1.2. Restraints
4.1.2.1. Side effects associated with solid tumor therapeutics
4.1.3. Opportunity
4.1.3.1. Rising research and development activities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Cancer Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type
9.2. Prostate Cancer*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Colorectal Cancer
9.4. Lung Cancer
9.5. Breast Cancer
9.6. Cervical Cancer
9.7. Others
10. By Drug Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.1.2. Market Attractiveness Index, By Drug Type
10.2. Carboplatin*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cisplatin
10.4. Gemcitabine
10.5. Paclitaxel
10.6. Doxorubicin
10.7. Bevacizumab
10.8. Erlotinib
10.9. Sunitinib
10.10. Everolimusa
10.11. Others
11. By End-user
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.1.2. Market Attractiveness Index, By End-user
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Clinics
11.4. Homecare
11.5. Others
12. By Distribution Channel
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Retail Pharmacies*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Hospital Pharmacies
12.4. Online Pharmacies
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. Company Profiles
15.1. Sanofi*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Amgen Inc.
15.3. AstraZeneca PLC
15.4. Baxter International Inc.
15.5. Biogen Inc.
15.6. Boehringer Ingelheim GmbH
15.7. Bristol-Myers Squibb Company
15.8. Eli Lilly and Company
15.9. F. Hoffmann-La Roche AG
15.10. GlaxoSmithKline PLC
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us